Rivia raises €13 million to modernize clinical trials
Zurich-based startup Rivia has secured €13 million in fresh funding to expand its agentic data engine, a platform designed to simplify and accelerate complex clinical trials. The company targets one of the most expensive and time‑consuming stages of drug development: generating high‑quality, regulatory‑grade evidence for new therapies.
An agentic data engine for real-world clinical complexity
Rivia is building an intelligent infrastructure layer that connects fragmented healthcare data, automates routine workflows, and supports advanced clinical research design. Its so‑called agentic data engine uses orchestrated AI agents to clean, harmonize and link data from hospitals, registries and trial sites, reducing manual data handling that often delays studies.
The platform aims to help pharmaceutical companies, contract research organizations and academic centers run more adaptive and decentralized trials, while maintaining strict compliance with regulatory and data privacy requirements. By standardizing data pipelines and automating eligibility checks, patient follow‑up and outcome tracking, Rivia seeks to shorten study timelines and lower operational costs.
Addressing mounting pressure on evidence generation
Drug developers are under growing pressure from regulators, payers and clinicians to provide robust, real‑world evidence on safety, efficacy and cost‑effectiveness. Traditional trial infrastructure, built around siloed systems and manual processes, struggles to keep pace with increasingly complex oncology, rare disease and precision medicine studies.
Rivia‘s model reflects a broader shift toward data‑centric, software‑defined research operations. By embedding AI algorithms directly into the data layer, the company aims to support more nuanced protocol designs, faster interim analyses and better patient stratification, without sacrificing data quality.
Scaling across Europe and beyond
The new capital will allow Rivia to expand its engineering and data science teams, deepen integrations with European hospital networks and extend its footprint to additional therapeutic areas. The startup also plans to strengthen partnerships with leading biotech and pharma companies that are looking to modernize their trial infrastructure.
As health systems digitize and regulators increasingly accept digital endpoints and real‑world data, platforms like Rivia‘s agentic data engine are positioned to become core components of the next generation of evidence generation in medicine.